Publications by authors named "K Bihan"
Background: Drug-induced interstitial lung disease (DI-ILD) is a heterogeneous subgroup of interstitial lung diseases (ILD). The number of molecules involved is increasing with time. Due to their low incidence, DI-ILDs may be detected only after a drug has been marketed, notably through Adverse Drug Reaction (ADR) reports to pharmacovigilance centres.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICIs) have been a major advance in cancer management. However, we still lack prospective real-world data regarding their usage in people with HIV infection (PWH).
Methods: The ANRS CO24 OncoVIHAC study (NCT03354936) is an ongoing prospective observational cohort study in France of PWH with cancer treated with ICI.
Importance: With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking.
Objective: To assess the risk of pregnancy-, fetal-, and/or newborn-related adverse outcomes associated with exposure to ICIs compared with exposure to other anticancer agents.
Design, Setting, And Participants: In this cohort study, all reports mentioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) used for a cancer indication registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted.
Article Synopsis
- The study examines the impact of COVID-19 vaccination safety reports on adverse reaction signal detection in pharmacovigilance databases like VigiBase, showing that July 2022 reports accounted for over 10% of total cases.
- It utilized the Information Component (IC) to analyze the relationship between reported adverse effects and COVID-19 vaccines by comparing a group of reports including vaccine cases (V+) to a group excluding them (V-).
- The results indicated a significant difference in potential signal detection, with "unexpected" adverse reactions losing signals when vaccine reports were excluded, while "expected" reactions often displayed new signals in the absence of those reports.
Article Synopsis
- Immune-checkpoint inhibitors (ICI) have transformed cancer treatment by utilizing the immune system, but they can cause serious, life-threatening immune-related adverse events (irAE) that can affect various organs.
- Analysis of data from the international pharmacovigilance database revealed 25 types of irAE across over 50,000 cases, with skin reactions and pneumonitis being the most common, and a shift in treatment regimens favoring anti-PD1 and anti-PDL1 therapies after 2016.
- Specific risk factors for certain irAE include cancer types and treatment regimens, with a median onset time for complications varying greatly; this underscores the importance of monitoring during ICI therapy